Scarica l'app Stockscreener
25.06
2.83%
-0.73
Dopo l'orario di chiusura:
25.10
0.04
+0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.79
Aprire:
$25.67
Volume 24 ore:
96.38M
Relative Volume:
1.52
Capitalizzazione di mercato:
$142.48B
Reddito:
$62.79B
Utile/perdita netta:
$9.84B
Rapporto P/E:
14.61
EPS:
1.7156
Flusso di cassa netto:
$10.38B
1 W Prestazione:
+2.58%
1M Prestazione:
+2.20%
6M Prestazione:
+13.81%
1 anno Prestazione:
-3.69%
Intervallo 1D:
$24.97
$25.77
Intervallo di 1 settimana:
$23.91
$26.48
Portata 52W:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.06 | 146.63B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,025.28 | 915.49B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
195.93 | 470.41B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.36 | 410.55B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.26 | 253.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
92.92 | 230.65B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Novo Chairman Blames Board Dropout on Former Employer Pfizer - livemint.com
Values that Pfizer and Delta CEOs draw on for great leadership - Yahoo Finance
Analysts’ Top Healthcare Picks: Candel Therapeutics (CADL), Pfizer (PFE) - The Globe and Mail
Pfizer's Rich Dividend Story Meets Overpriced Metsera Acquisition/Patent Cliff Risks - Seeking Alpha
Is Pfizer Stock a Buy After This $10 Billion Acquisition? - MSN
Starboard Value Calls It Quits On Its Pfizer Investment - Finimize
Activist Starboard sells Pfizer stake after pushing for changes - Reuters
Starboard Value Takes Significant Stake in BILL, Exits Pfizer - GuruFocus
Starboard's Q3 moves show previously disclosed new stake in BILL, Pfizer exit (BILL:NYSE) - Seeking Alpha
Law360 Pulse Spotlight On Mid-Law Work - Law360
Starboard Value LP dissolves share stake in Pfizer & Fortrea - MarketScreener
Taxation With Representation: Wachtell, Paul Hastings, Sidley - Law360
Metsera acquisition 'could be a key tailwind' for Pfizer - The Business Journals
Why Pfizer (PFE) Shares Are Sliding Today - Finviz
Pfizer 3Q Results - Contract Pharma
Novo’s new chairman urged to curb risk after Metsera drama - The Detroit News
Pfizer Reportedly Planning To Divest BioNTech Stake - BioSpace
New GIPR antagonists disclosed in Pfizer patent - BioWorld MedTech
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Rothschild & Co Redburn Adjusts Price Target on Pfizer to $24 From $25, Maintains Neutral Rating - MarketScreener
Pfizer Cuts BioNTech Stake by More Than Half - TradingView
Why analysts remain bullish on Pfizer Inc. stockTrade Analysis Report & Weekly Stock Performance Updates - Fundação Cultural do Pará
Will Pfizer Inc. stock test record highs in 2025July 2025 Pullbacks & Low Risk Entry Point Guides - Fundação Cultural do Pará
Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal - Yahoo Finance
Pfizer Stock Slips Premarket Despite Completing Metsera Deal; Investors React To BioNTech Stake Cut - Stocktwits
Pfizer Strengthens Pipeline With $10B Metsera Deal Amid Solid Q3 Results - Seeking Alpha
Pfizer completes Metsera acquisition in deal worth up to $10 bn - El Paso Inc.
Pfizer’s former R&D chief Dolsten pulls out of Novo Nordisk board race - 104.1 WIKY
Pfizer And Novo Nordisk Make Major Moves In Health Care - Finimize
Pfizer Buys Metsera To Jumpstart Its Obesity Drug Ambitions - Finimize
Pfizer's $10 Billion Obesity Drug Deal Could Reshape Treatment for 137 Million Americans - Stansberry Research
Pfizer slashes stake in COVID vaccine partner BioNTech - 104.1 WIKY
AK Health Dept. mails Pfizer-funded flyers telling Alaskans to vax to avoid illness, death - Alaska Watchman
Pfizer's former R&D chief Dolsten pulls out of Novo Nordisk board race - MarketScreener
Pfizer's ex-R&D chief Dolsten withdraws from Novo Nordisk board race - Yahoo Finance
Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up By Reuters - Investing.com
Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up - Reuters
Pfizer Slashes Stake in COVID Vaccine Partner BioNTech - US News Money
Wachtell-Led Pfizer Closes Metsera Deal Worth Up To $10B - Law360
Pfizer Completes Acquisition of Metsera for $7 Billion - TipRanks
Pfizer completes $7 billion acquisition of Metsera with milestone payments - Investing.com
Pfizer completes $7 billion acquisition of Metsera with milestone payments By Investing.com - Investing.com South Africa
Pfizer completes acquisition of Metsera - MLex
Pfizer CEO says RFK Jr. wasn't his 'first choice' for HHS Secretary - Yahoo Finance
Pfizer CEO vows company will be a ‘formidable competitor’ in booming weight-loss market after $10B buy - MSN
Metsera holders vote to approve $10B sale to Pfizer, deal closes (update) (MTSR:NASDAQ) - Seeking Alpha
Is Pfizer Stock A Buy After It Clinches The $10 Billion Takeover Of Metsera? - Investor's Business Daily
Pfizer Dumps BioNTech Stake as Obesity Gold Rush Heats Up - Yahoo Finance
Metsera shareholders vote for up to $10 billion acquisition by Pfizer - 104.1 WIKY
CT’s Pfizer acquires obesity drug start-up. A ‘strategic milestone,’ pharmaceutical giant CEO said - Hartford Courant
Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market - Yahoo Finance
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):